Patent ductus arteriosus: From pharmacology to surgery

Jamie E Anderson; Brian H Morray; Mihai Puia-Dumitrescu; David H Rothstein

doi:10.1016/j.sempedsurg.2021.151123

Patent ductus arteriosus: From pharmacology to surgery

Semin Pediatr Surg. 2021 Dec;30(6):151123. doi: 10.1016/j.sempedsurg.2021.151123. Epub 2021 Oct 23.

Authors

Jamie E Anderson¹, Brian H Morray², Mihai Puia-Dumitrescu³, David H Rothstein⁴

Affiliations

¹ Pediatric General and Thoracic Surgery, University of Washington Medical School, Seattle Children's Hospital, 4800 Sand Point Way NE, OA.9.220, Seattle, WA, USA.
² Pediatric Cardiology, University of Washington Medical School, Seattle Children's Hospital, Seattle, WA, USA.
³ Neonatology, University of Washington Medical School, Seattle Children's Hospital, Seattle, WA, USA.
⁴ Pediatric General and Thoracic Surgery, University of Washington Medical School, Seattle Children's Hospital, 4800 Sand Point Way NE, OA.9.220, Seattle, WA, USA. Electronic address: David.Rothstein@seattlechildrens.org.

PMID: 34930590
DOI: 10.1016/j.sempedsurg.2021.151123

Abstract

Patent ductus arteriosus (PDA) may be found in 0.1-0.2% of term infants, but the average incidence is at least five-fold higher in premature infants, correlating inversely with birth weight and gestational age. While not all patients with a PDA require treatment, the deleterious effects of persistent left-to-right shunting across the ductus can have important short- and long-term consequences. Medical and interventional approaches to PDA closure have evolved greatly in the past decade and add to the decision-making pathways. This article summarizes the pathophysiology of PDA and characterizes the medical, surgical and endovascular treatment approaches.

Keywords: Patent ductus arteriosus; Transcatheter closure.

MeSH terms

Ductus Arteriosus, Patent* / surgery
Humans